Bispecific CAR T cells for B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new type of cell therapy that engineers your own immune cells to find and attack cancer cells that have either CD19 or CD20 markers. It is for people with B-cell lymphomas or leukemias that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a B-cell cancer (like lymphoma or leukemia) that has returned or not responded to standard care, including previous CAR T-cell therapy.
- Your cancer cells show CD19 or CD20 markers.
- You are generally able to care for yourself (ECOG 0-2).
- Your major organs (heart, lungs, liver, kidneys, bone marrow) are functioning well enough.
- You are willing to use highly effective birth control and, if female, have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.